New CEOs Need Digit...
Health Care: Drugs
Onyx Pharmaceuticals Inc. (ONXX: NASDAQ)
$85.54 -3.26 | -3.67%
06/19/13 - 04:00 PM ET
Latest Dividend:0.00
Latest Dividend Yield:0.00%
Dividend Ex-Date:12/31/69
Price Earnings Ratio:n/a
Price Earnings Comparisons:
| ONXX | Sector Avg. | S&P 500 |
|---|---|---|
| n/a | 0.00 | 17.70 |
Price Performance History (% change):
| 3 Mo | 1 Yr | 3 Yr |
|---|---|---|
| 2.53 | 94.06 | 280.14 |
| GROWTH | 12 Mo | 3 Yr | CAGR |
|---|---|---|---|
| Revenue | -19.00 | 0.44 | 0.13 |
| Net Income | -100.00 | -12.62 | 0.00 |
| EPS | -100.00 | -11.67 | 0.00 |
Earnings for ONXX:
| EBITDA | -188.00 |
| REVENUE | 362.17M |
Average Earnings Estimates
| Qtr (06/13) | Qtr (09/13) | FY (12/13) | FY (12/14) | |
|---|---|---|---|---|
| Average Estimate | $-0.62 | $-0.70 | $-2.46 | $-0.29 |
| Number of Analysts | 5 | 5 | 5 | 5 |
| High Estimate | $-0.44 | $-0.53 | $-2.11 | $0.87 |
| Low Estimate | $-0.86 | $-0.87 | $-2.93 | $-1.76 |
| Prior Year | $-0.85 | $-0.89 | $-3.04 | $-2.46 |
| Growth Rate (Year over Year) | 26.82% | 21.57% | 18.95% | 88.39% |
Portfolios with ONXX
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- Contributor4 Drug Stocks Facing FDA Ap...
- ContributorHot Biotech Stocks Traded b...
- ContributorStocks Rising On Unusual Vo...
- Userplayers
- ContributorBreakout Stocks Of The Week...
- ContributorEarnings Short Squeeze Play...
- ContributorStocks Rising On Unusual Vo...
Latest ONXX Headlines from TheStreet
- Onyx Pharmaceuticals Inc. (ONXX): Today's Featured Drugs Laggard 06.18.13 | 05:06 pm
- DVAX, RDY, ONXX, ALXN And VRX, 5 Health Care Stocks Pushing The Sector Lower 06.10.13 | 01:06 pm
- FDA's Flawed Call On Aveo's Tivozanib 06.07.13 | 05:06 pm
- Aveo's Future Depends on Triple-Negative Breast Cancer 06.06.13 | 08:06 am
- Onyx Stock Falls On Unusually High Volume (ONXX) 06.03.13 | 03:06 pm
- ASCO '13: Onyx's Nexavar Delays Growth of Thyroid Cancer 06.02.13 | 07:06 am
- Aveo Chairman: Expect 'Consequences" From Kidney Cancer Drug Debacle 05.29.13 | 11:05 am
- Onyx Pharmaceuticals Inc. Stock Hold Recommendation Reiterated (ONXX) 05.24.13 | 10:05 am
- 5 Stocks Raising The Drugs Industry Higher 05.23.13 | 01:05 pm
- Onyx Pharmaceuticals Inc. (ONXX): Today's Featured Drugs Laggard 05.21.13 | 05:05 pm
Press Releases for ONXX
- Phase 3 DECISION Trial Investigating The Use Of Nexavar® (sorafenib) Demonstrated Significant Improvement In Progression-Free Survival In Patients With Radioactive Iodine-Refractory Differentiated Thyroid Cancer - PR Newswire 06.02.13 | 07:06 am
- Bayer's Stivarga® (regorafenib) Tablets Approved In Japan - PR Newswire 03.25.13 | 05:03 pm
- Bayer's Stivarga® (regorafenib) Tablets Approved By U.S. FDA For Treatment Of Patients With Locally Advanced, Unresectable Or Metastatic GIST - PR Newswire 02.25.13 | 04:02 pm
- Onyx Pharmaceuticals Launches Make Your Mark At The Multiple Myeloma Experience To Champion Progress In Multiple Myeloma Research And Treatment - PR Newswire 12.06.12 | 04:12 pm
- Onyx Pharmaceuticals To Present At Upcoming Investor Conferences - PR Newswire 09.04.12 | 04:09 pm
- Bayer Submits New Drug Application For Regorafenib For The Treatment Of Gastrointestinal Stromal Tumors (GIST) - PR Newswire 08.30.12 | 10:08 am
- Onyx Pharmaceuticals Announces Kyprolis⢠Study Published In The Medical Journal Blood - PR Newswire 07.25.12 | 09:07 am
- Onyx Pharmaceuticals To Report Second Quarter 2012 Financial Results After Market On August 1, 2012 - PR Newswire 07.23.12 | 04:07 pm
- Addition Of Tarceva® (erlotinib) To Nexavar® (sorafenib) Did Not Provide Additional Benefit To Patients With Unresectable Liver Cancer Versus Nexavar Alone In Phase 3 Trial - PR Newswire 07.23.12 | 02:07 am
- Onyx Pharmaceuticals Receives FDA Accelerated Approval Of Kyprolis⢠(carfilzomib) For Injection - PR Newswire 07.20.12 | 12:07 pm
Partner Headlines for ONXX
- Short Interest Falls in Vertex, Rises in Biogen Idec (VRTX, BIIB) - Benzinga 06.12.13 | 01:06 pm
- Onyx Phase 3 Nexavar DECISION Trial Shows Significant Improvement in Progression-Free Survival in Patients with Radioactive Iodine-Refractory Differentiated Thyroid Cancer - Benzinga 06.02.13 | 09:06 am
- Onyx Pharma to Hold Call to Discuss Phase 3 DECISION Data at 2013 ASCO - Benzinga 05.31.13 | 04:05 pm
- Short Interest in Vertex Rises, in Celgene Falls - Benzinga 05.11.13 | 10:05 am
- Pharmacyclics Inc. (PCYC): Today's Most Compelling Stock Buy - NASDAQ 05.07.13 | 05:05 pm
- Onyx Pharmaceuticals Earnings: Here’s Why Investors are Buying Shares Now - Wall St. Cheat Sheet 05.07.13 | 06:05 am
- Polycyclics Inc. (PCYC): Today's Most Compelling Stock Pick - NASDAQ 04.26.13 | 07:04 pm
- Deutsche Bank Reiterates Buy on Onyx Pharmaceuticals on Updated Guidelines - Benzinga 03.11.13 | 01:03 pm
- Four Biotech Stocks On The Clock - Seeking Alpha 02.19.13 | 09:02 am
- Onyx Pharmaceuticals (ONXX) - Bull of the Day - Zacks 12.05.12 | 01:12 am
